Treatment of onychomycosis caused by dermatophytes--an opinion proposed by Committee for Standardization of the Japanese Society for Medical Mycology 2007.
After the rapid progress in therapeutic pharmaceutics against onychomycosis caused by dermatophytes in the 1990s, an optimal therapeutic strategy for individual patients with the onychomycosis has become possible for clinical dermatologists. In this review, we discuss on clinical problems concerning this disease and propose recommendable treatments for each patient with topical and/or systemic use of antifungal agents. Finally, with consideration of already published therapeutic guidelines, we stress the necessity of "order-made" therapy for each patient with his/her medical status and wishes taking into account.
Mohri
Shinobu
S
Yokohama City Hospital.
Watanabe
Shinichi
S
Toshio
Kusunoki
K
Shibuya
Kazutoshi
K
Nishiyama
Yayoi
Y
Abe
Michiko
M
Uno
Jun
J
Oguri
Toyoko
T
Maeasaki
Shigefumi
S
Ikeda
Reiko
R
Abe
Shigeru
S
D000284:Administration, Oral; D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage*; D003883:Arthrodermataceae; D003881:Dermatomycoses / Q000382:microbiology* / Q000628:therapy*; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage*; D007564:Japan; D009172:Mycology; D009281:Naphthalenes / Q000008:administration & dosage*; D014009:Onychomycosis / Q000382:microbiology* / Q000628:therapy*; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D017964:Itraconazole; D000077291:Terbinafine